September 12, 2019
Takeda Pharmaceutical Company Limited
PwC Consulting LLC
Osaka, Japan and Tokyo, Japan, September 12 2019 - Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") and PwC Consulting LLC ("PwC Consulting") have entered into an agreement to push the boundaries of disease modelling and simulation technologies by applying PwC’s Bodylogical® ("Bodylogical") for Crohn’s disease.
Bodylogical is a modelling and simulation platform developed by PwC that mirrors the functions of the human body to create a digital twin – a computer generated patient. The Digital twin can be personalized with clinical and drug treatment information to match an individual patient under various treatment scenarios. Developed using medical science and published research, the digital twin can help predict the potential condition of a patient. The results of predictions are shown on a tablet screen.
As an initial application, Takeda will introduce the digital twin simulator to gastroenterologists in Japan. The model will be updated and refined and the two companies aim to have a final version ready by March, 2020. In the future, the digital twin simulator will be available to healthcare professionals to support the management of Crohn's disease by helping predict clinical outcomes at an individual level.
Jovelle Fernandez, Head, Japan Medical Office at Takeda, remarked "Crohn's disease is a complex inflammatory bowel disease. The number of patients with Crohn's disease is rapidly increasing in Japan, where there are currently over 40,000 patients. It is characterized by chronic, relapsing, remitting inflammation and clinical symptoms, and many patients experience strong difficulties in their daily and professional lives from it. This is therefore, an exciting opportunity to leverage technology as we continue with our commitment to patients via various projects from the Patient First Program."
PwC has invested heavily to create breakthroughs in precision healthcare, developing patented solutions like Bodylogical that are groundbreaking innovations. Bodylogical, originally developed in the US, has been customized for Japan, where it was launched in May 2018. Yujiro Tsutsumi, PwC Consulting Partner and Bodylogical Japan Leader said, "As a world leader in therapeutic innovation, Takeda quickly understood the unique value of PwC’s new model of healthcare consulting that includes Biomedical Engineers, Data Scientists and Experience Designers, all working together with the aim of providing insights that can complement and accelerate traditional approaches and potentially revolutionize the delivery of therapies to patients."
PwC will continue to work with Takeda to design, test and launch digital engagement tools that aim to improve patient outcomes with the unique capabilities of disease modelling and simulation.
Patient First Program is Takeda’s Integrated Care Initiative. Integrated Care includes initiatives seeking to improve outcomes of care by overcoming issues of fragmentation though linkage or co-ordination of series of providers along the continuum of care. This initiative works in collaboration with various stakeholders involved in the health care ecosystem which includes the patients, the providers, allied health care providers such as nurses and pharmacists. This initiative is led by Japan Medical Office which is independent of our commercial and sales division to better understand provision of Integrated Care to patients.
Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. Recognizing this unmet need, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years. Takeda aspires to advance how patients manage their disease. Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries and regions.
At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 158 countries with more than 250,000 people who are committed to delivering quality in assurance, advisory and tax services.
PwC Consulting LLC offers comprehensive consulting services from strategy through execution. In collaboration with the PwC global network we work to resolve complex and challenging management issues faced by our clients, helping them bolster their competitive advantage in the global market.
Bodylogical® is PwC’s scientifically-developed predictive engine that mechanistically simulates the human body and its functions by mirroring the body’s own physiological systems—circulatory, respiratory, digestive, endocrine, renal, and more—to create a unique model of every unique life.
© 2004 - 2019 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.